Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
暂无分享,去创建一个
B. Zinman | M. Sabatine | K. Mahaffey | C. Wanner | V. Perkovic | D. Wheeler | D. McGuire | S. Wiviott | I. Raz | R. Agarwal | H. Heerspink | A. Pong | T. Toyama | B. Neuen | C. Arnott | D. Cherney | M. Oshima | A. Langkilde | Robert Edwards | B. Neal
[1] G. Filippatos,et al. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy , 2021, Kidney international reports.
[2] C. Cannon,et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. , 2021, European heart journal.
[3] G. Filippatos,et al. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. , 2021, Journal of the American College of Cardiology.
[4] N. Tangri,et al. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence. , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[5] P. Ponikowski,et al. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. , 2021, JACC. Heart failure.
[6] J. Butler,et al. Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction , 2021, Heart Failure Reviews.
[7] P. Lawler,et al. Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes , 2021, Diabetes Care.
[8] H. Heerspink,et al. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial , 2020, Diabetes Care.
[9] G. Filippatos,et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.
[10] C. Cannon,et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.
[11] K. Khunti,et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2020, Kidney international.
[12] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[13] C. Cannon,et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.
[14] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[15] G. Filippatos,et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.
[16] S. Solomon,et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.
[17] C. Mathieu,et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetes Care.
[18] D. Gilbertson,et al. Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.
[20] A. Levin,et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.
[21] J. Carrero,et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.
[22] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[23] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[24] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[25] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.
[26] M. Landray,et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study , 2018, Clinical kidney journal.
[27] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[28] V. Perkovic,et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. , 2015, The Cochrane database of systematic reviews.
[29] C. Kovesdy. Epidemiology of hyperkalemia: an update. , 2016, Kidney international supplements.
[30] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[31] B. Palmer. Regulation of Potassium Homeostasis. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[32] D. de Zeeuw,et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.
[33] Josef Coresh,et al. Chronic kidney disease , 2012, The Lancet.
[34] F. Karet. Mechanisms in hyperkalemic renal tubular acidosis. , 2009, Journal of the American Society of Nephrology : JASN.
[35] K. Johnson. An Update. , 1984, Journal of food protection.